Shots:
Biocytogen & Acepodia have entered into a strategic collaboration to evaluate dual-payload bispecific antibody-drug conjugate (BsAD2C) program in complex tumors by combining the former's RenLite platform with Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) tech
Under the agreement, Biocytogen will provide a bispecific antibody from its RenLite platform, while Acepodia will combine 2 distinct payloads using…
Shots:
Avenzo Therapeutics and DualityBio have signed an exclusive license agreement to develop, manufacture & commercialize the former’s AVZO-1418/DB-1418 across the globe (excl. Greater China)
As per the terms, DualityBio will get $50M upfront, ~$1.15B development, regulatory and commercial milestones as well as tiered royalties in Avenzo’s territory
AVZO-1418, an EGFR/HER3-targeting ADC developed…
Shots:
Alloy Therapeutics and Sanofi have entered into a target specific partnership to leverage Alloy's AntiClastic Antisense Platform for a CNS target
Sanofi will utilize its neuroscience expertise to develop genetic medicines that cross the blood-brain barrier. It will pay up to $27.5M as upfront & near-term preclinical milestones as well as $400M as…
Shots:
Orna & Vertex have entered into a 3yrs. strategic research collaboration to utilize the former’s LNP delivery solutions for supporting the development of next-gen. gene editing therapies for SCD & TDT, with Vertex funding the partnership
As per the terms, Orna will get $65M upfront (incl. investment in the form of a convertible…
Shots:
JCR Pharmaceuticals & Modalis have reported successful validation of initial PoC to develop gene therapy targeting CNS disease and will advance to the next phase under a new joint agreement
The new agreement aims at conducting preclinical studies for gene therapy using JCR's BBB-crossing J-Brain Cargo tech and for gene therapy payload using Modalis' CRISPR-GNDM…
This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & Biotech. Check out our full report below:
Novartis Reports Data from P-III (STEER) Study of Onasemnogene Abeparvovec to Treat Children and Young Adults with Spinal Muscular Atrophy (SMA)
Read More: Novartis
CARsgen Therapeutics Reports Topline Results from P-II…
Shots:
Pharmanovia has signed an exclusive in-licensing agreement with Radius Health for abaloparatide (US brand name: Tymlos) to treat osteoporosis, expanding its osteoporosis franchise
Pharmanovia will handle clinical, regulatory & commercial responsibilities across APAC region (China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau & Philippines), while Radius will get an upfront, regulatory…
Shots:
Innovent & Roche have entered into a collaboration & exclusive license agreement for developing IBI3009 to treat advanced SCLC
As per the terms, Roche secures exclusive worldwide rights to develop, manufacture & commercialize IBI3009 plus will lead full development after early-stage studies, conducted jointly. Innovent will get $80M upfront, up to $1B development…
Shots:
Sangamo regains rights to giroctocogene fitelparvovec (gene therapy for hemophilia A) as Pfizer ends their collaboration (effective Apr 21, 2025) & decids not to file BLA or MAA to pursue commercialization. Sangamo plans to seek a new partner
The drug is in P-III (AFFINE) trial involving 75 adult males with severe hemophilia A…
Shots:
Brii Bio & VBI Vaccines have signed an asset purchase agreement to acquire IP rights of BRII-179 (novel recombinant protein-based HBV immunotx., expressing Pre-S1, Pre-S2 & S HBV surface antigens)
As per the terms, Brii will acquire BRII-179’s patents, know-how & associated materials for $18M (eliminating all future milestones & royalty obligations). Prior…

